Ablynx and Procter & Gamble extend Nanobody drug discovery development agreement to metabolic targets
11-Apr-2006
Under terms of the agreement, P&GP provides Ablynx with research and development funding, milestone payments, and royalties upon commercialization. Ablynx is responsible for discovering Nanobodies(TM) that meet an agreed product profile. P&GP assumes responsibility for the pre-clinical and clinical development of lead Nanobodies(TM), as well as the commercialization of any resulting drug products. The financial terms of the agreement are not disclosed.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.